2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

2887 Anti-hemojuvelin monoclonal antibody increased hemoglobin and iron mobilization in combination with momelotinib in wild-type mice

Julia Xu, PhD, Min Wu, PhD2
1 Disc Medicine, Watertown, Massachusetts, United States
2 Disc Medicine, Watertown, Massachusetts, United States

Background: Myelofibrosis (MF) is a hematologic malignancy characterized by progressive bone marrow fibrosis and ineffective erythropoiesis. Anemia is a common complication of MF. Momelotinib (MMB) is a Janus kinase (JAK)1/JAK2 inhibitor with additional activin A receptor type 1 (ACVR1) inhibitory activity and is approved for adult patients with intermediate or high-risk MF with anemia.

Selcodebart (DISC-0974) is a humanized anti-hemojuvelin (HJV) monoclonal antibody. It was designed to disrupt the interaction between HJV and the bone morphogenetic protein (BMP) receptor complex, leading to decreased hepcidin and increased iron availability for enhanced erythropoiesis. In a Phase 2 study of anemia in MF (NCT05320198), selcodebart has shown efficacy alone and in combination with JAK inhibitors, including MMB. A previous study demonstrated that DBIO-100, a murine surrogate of selcodebart, alleviated ruxolitinib-induced anemia and enhanced serum iron availability in vivo (Xu et al, Blood 2024). This study investigated the effects of DBIO-100 in combination with MMB on hematologic responses in wild-type mice.

Methods: Wild-type C57BL/6J male mice were randomized to receive vehicle (once a week via intravenous route), MMB (10, 20, or 40 mg/kg twice a day via oral route), DBIO-100 (20 mg/kg once a week via intravenous route), or a combination of MMB/DBIO-100 for 28 days. At study completion, blood and serum samples were collected for hematologic and iron analyses.

Results: DBIO-100 increased hemoglobin (Hgb) both as a single agent and in combination with MMB at all MMB dose levels evaluated.

Both DBIO-100 and MMB increased mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) as single agents, whereas the combination treatment produced greater increases in MCH than MMB alone. DBIO-100 also increased mean corpuscular hemoglobin concentration (MCHC) as a single agent, and combination treatment produced greater increases in MCHC than MMB alone. Lastly, both DBIO-100 and MMB increased reticulocyte Hgb as single agents, whereas the combination treatment produced greater increases than MMB alone.

MMB treatments caused modest increases in serum iron and transferrin saturation (TSAT) at 10 and 20 but not 40 mg/kg. DBIO-100, either as a single agent or in combination with MMB, led to significant increases in serum iron and TSAT.

Conclusions: DBIO-100 increased Hgb both as monotherapy and in combination with MMB across all MMB dose levels evaluated. In addition, combining DBIO-100 with MMB increased serum iron and TSAT compared with MMB alone. These findings support the therapeutic potential of anti-HJV monoclonal antibodies for the treatment of anemia, either as monotherapy or in combination with JAK inhibitors in diseases such as MF.

Julia Xu, PhD: Disc Medicine - Current equity holder in publicly-traded company; Disc Medicine - Stock (publicly traded); Disc Medicine - Divested equity in a private or publicly-traded company in the past 24 months; Disc Medicine - Current Employment